Search Results - "Barugh, Kate"

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    Routine versus As-Needed Bevacizumab with 12-Weekly Assessment Intervals for Neovascular Age-Related Macular Degeneration

    Routine versus As-Needed Bevacizumab with 12-Weekly Assessment Intervals for Neovascular Age-Related Macular Degeneration by Mahmood, Sajjad, FRCOphth, Roberts, Stephen A., PhD, Aslam, Tariq M., FRCOphth, PhD, Parkes, Jeremy, BSc, MCOptom, Barugh, Kate, BA Hons, Bishop, Paul N., FRCOphth, PhD

    Published in Ophthalmology (Rochester, Minn.) (01-07-2015)
    “…Purpose To evaluate the efficacy and safety of intravitreal bevacizumab (Avastin; Genentech, South San Francisco, CA) in patients with neovascular age-related…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  2. 2
    Routine versus As-Needed Bevacizumab with 12-Weekly Assessment Intervals for Neovascular Age-Related Macular Degeneration: 92-Week Results of the GMAN Trial

    Routine versus As-Needed Bevacizumab with 12-Weekly Assessment Intervals for Neovascular Age-Related Macular Degeneration: 92-Week Results of the GMAN Trial by Mahmood, Sajjad, Roberts, Stephen A, Aslam, Tariq M, Parkes, Jeremy, Barugh, Kate, Bishop, Paul N

    Published in Ophthalmology (Rochester, Minn.) (01-07-2015)
    “…To evaluate the efficacy and safety of intravitreal bevacizumab (Avastin; Genentech, South San Francisco, CA) in patients with neovascular age-related macular…”
    Get full text
    Journal Article
    Save to List
    Saved in:

Search Tools: